edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Shield Therapeutics
Edison Investment Research is terminating coverage on Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Shield Therapeutics — 2 videos in collection
Shield Therapeutics is a UK-based, speciality pharmaceutical company with a primary focus on commercialising its drug Feraccru, which is approved in Europe for the treatment of iron deficiency, with or without anaemia. In this video , healthcare analyst Dr Sean Conroy provides an overview of Shield Therapeutics and outlines the company’s strategy for the commercialisation of Feraccru. He finishes the video by detailing Edison’s approach to valuing the company.
See latest research note here.
Get access to the very latest content matched to your personal investment style.